Auro-Canagliflozin Recall - Incorrect DIN on Blister Cards
Summary
Health Canada issued a Type III recall for Auro-Canagliflozin 300mg tablets (DIN 02510375) manufactured by Auro Pharma Inc. due to incorrect Drug Identification Number on blister cards. Affected lots XQ3025001A and XQ3025004A are impacted. The recall applies to wholesalers with a depth limited to wholesale distribution.
What changed
Health Canada issued a Type III health product recall for Auro-Canagliflozin (Canagliflozin 300mg tablets) distributed by Auro Pharma Inc. The recall affects two lots (XQ3025001A, XQ3025004A) that are labelled with an incorrect DIN found on the blister card. The identification number for this recall is RA-81816.
Wholesalers should immediately verify if their inventory includes the affected lots, remove affected product from distribution, and contact the recalling firm with any questions. Patients using this medication should consult their healthcare provider before discontinuing use. Healthcare providers and patients should report any adverse reactions or health product safety complaints to Health Canada.
What to do next
- Verify if your inventory contains affected lots XQ3025001A or XQ3025004A
- Remove affected product from distribution channels
- Contact Auro Pharma Inc. with questions about the recall
- Report any adverse reactions or health product safety concerns to Health Canada
Archived snapshot
Apr 1, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Health product recall
Auro-Canagliflozin: Affected lots are labelled with the incorrect DIN found on the blister card.
Brand(s)
Last updated
2026-03-31
Summary
Product Auro-Canagliflozin Issue Health products - Product safety What to do Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| Auro-Canagliflozin | Auro-Canagliflozin | DIN 02510375 | Tablet | Canagliflozin 300mg | XQ3025001A, XQ3025004A |
Issue
Affected lots are labelled with the incorrect DIN found on the blister card.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Wholesalers
Details
Original published date:
2026-03-31
Alert / recall type Health product recall Category Health products - Drugs Companies
Auro Pharma Inc.
3700 Steeles Avenue West, Suite 402,
Woodbridge, Ontario
L4L 8K8
Published by Health Canada Audience General public Healthcare Industry Recall class Type III Recall date
2026-03-31
Identification number RA-81816
Get notified
Receive emails about new and updated recall and safety alerts.
Related changes
Get daily alerts for Health Canada Recalls & Safety Alerts
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from Health Canada.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Health Canada Recalls & Safety Alerts publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.